Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
February 26 2020 - 1:46PM
Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage
immunotherapy company, today announced the closing of its
previously announced registered direct offering to certain
institutional investors of 1,000,000 ordinary shares of the Company
at a purchase price of $8.00 per share for aggregate gross proceeds
of $8.0 million.
H.C. Wainwright & Co. acted as the exclusive placement agent
for the offering.The Company intends to use the net proceeds from
the offering for clinical, regulatory, manufacturing and research
and development activities, potential acquisitions and
in-licensing, as well as for working capital and other general
corporate purposes.
A shelf registration statement on Form F-3 (File No. 333-232009)
relating to the ordinary shares offered in the registered direct
offering was filed with the Securities and Exchange Commission (the
“SEC”) on June 7, 2019 and declared effective by the SEC on June
21, 2019. The offering was made only by means of the written
prospectus and prospectus supplement that form a part of such shelf
registration statement. A final prospectus supplement related to
the offering has been filed with the SEC and may be obtained for
free by visiting EDGAR on the SEC website at www.sec.gov.
Electronic copies of the final prospectus supplement and the
accompanying prospectus relating to the offering may also be
obtained by contacting H.C. Wainwright & Co., LLC, 430 Park
Avenue, 3rd Floor, New York, NY 10022, or by calling (646) 975-6996
or by emailing placements@hcwco.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein or
any other securities, nor shall there be any sale of the securities
described herein or any other securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
ABOUT ENLIVEX Enlivex is a clinical stage
immunotherapy company, developing an allogeneic drug pipeline for
immune system rebalancing. Immune system rebalancing is critical
for the treatment of life-threatening immune and inflammatory
conditions which involve an out of control immune system (e.g.
Cytokine Release Syndrome) and for which there are no approved
treatments (unmet medical needs), as well as solid tumors
immune-checkpoint rebalancing. For more information, visit
http://www.enlivex.com.
Safe Harbor Statement: This press release contains
forward-looking statements, which may be identified by words such
as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,”
“believes,” “should,” “would”, “intends,” “estimates,” “suggests,”
“has the potential to” and other words of similar meaning,
including statements regarding the anticipated use of the proceeds
of the registered direct offering, expected cash balances, market
opportunities for the results of current clinical studies and
preclinical experiments, the effectiveness of, and market
opportunities for, ALLOCETRATM programs, which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
forward-looking statements involve risks and uncertainties that may
affect Enlivex’s business and prospects, including the risks that
Enlivex may not succeed in generating any revenues or developing
any commercial products; that the products in development may fail,
may not achieve the expected results or effectiveness and/or may
not generate data that would support the approval or marketing of
these products for the indications being studied or for other
indications; that ongoing studies may not continue to show
substantial or any activity; market and other conditions; and other
risks and uncertainties that may cause results to differ materially
from those set forth in the forward-looking statements. The results
of clinical trials in humans may produce results that differ
significantly from the results of clinical and other trials in
animals. The results of early-stage trials may differ significantly
from the results of more developed, later-stage trials. The
development of any products using the ALLOCETRATM product line
could also be affected by a number of other factors, including
unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact
of pharmaceutical industry regulation, the impact of competitive
products and pricing and the impact of patents and other
proprietary rights held by competitors and other third
parties. In addition to the risk factors described above,
investors should consider the economic, competitive, governmental,
technological and other factors discussed in Enlivex’s filings with
the Securities and Exchange Commission, including under the heading
“Risk Factors” contained in Enlivex’s most recently filed Annual
Report on Form 20-F, as amended. The forward-looking
statements contained in this press release speak only as of the
date the statements were made, and we do not undertake any
obligation to update forward-looking statements, except as required
under applicable law.
ENLIVEX CONTACT: Shachar Shlosberger, CFO Enlivex Therapeutics
Ltd.shachar@enlivex-pharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024